Deep Track Capital
Latest statistics and disclosures from Deep Track Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are INSM, JAZZ, ITCI, IONS, GH, and represent 26.36% of Deep Track Capital's stock portfolio.
- Added to shares of these 10 stocks: GH (+$76M), ITCI (+$55M), AXSM (+$53M), APGE (+$51M), NVCR (+$40M), HLVX (+$39M), PACB (+$38M), NTLA (+$37M), NBIX (+$34M), EDIT (+$29M).
- Started 16 new stock positions in OLMA, ANAB, NBIX, MRNA, APGE, SYRS, AMLX, BNTX, NVAX, HLVX. SRRK, Orchard Therapeutics, AGIO, TXG, SLRN, NVCR.
- Reduced shares in these 10 stocks: IMVT (-$101M), GPCR (-$37M), JAZZ (-$15M), INSM (-$13M), Orchard Therapeutics Plc ads (-$11M), INZY (-$9.2M), ZNTL (-$8.5M), BEAM (-$7.3M), ANIP (-$6.6M), ETNB (-$6.4M).
- Sold out of its positions in ALLK, FGEN, IMUX, INZY, INKT, MLTX, Orchard Therapeutics Plc ads, ZNTL.
- Deep Track Capital was a net buyer of stock by $517M.
- Deep Track Capital has $2.6B in assets under management (AUM), dropping by 19.93%.
- Central Index Key (CIK): 0001856083
Tip: Access up to 7 years of quarterly data
Positions held by Deep Track Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Deep Track Capital
Deep Track Capital holds 63 positions in its portfolio as reported in the September 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Insmed Com Par $.01 (INSM) | 5.8 | $152M | -7% | 6.0M | 25.25 |
|
Jazz Pharmaceuticals Shs Usd (JAZZ) | 5.7 | $147M | -8% | 1.1M | 129.44 |
|
Intra Cellular Therapies (ITCI) | 5.2 | $135M | +67% | 2.6M | 52.09 |
|
Ionis Pharmaceuticals (IONS) | 5.0 | $129M | 2.8M | 45.36 |
|
|
Guardant Health (GH) | 4.6 | $120M | +170% | 4.1M | 29.64 |
|
Immunovant (IMVT) | 4.1 | $107M | -48% | 2.8M | 38.39 |
|
Alkermes SHS (ALKS) | 4.1 | $106M | +26% | 3.8M | 28.01 |
|
Dynavax Technologies Corp Com New (DVAX) | 3.9 | $100M | +3% | 6.8M | 14.77 |
|
Structure Therapeutics Sponsored Ads (GPCR) | 3.7 | $97M | -27% | 1.9M | 50.42 |
|
Pliant Therapeutics (PLRX) | 3.7 | $95M | +35% | 5.5M | 17.34 |
|
Springworks Therapeutics (SWTX) | 3.2 | $82M | 3.5M | 23.12 |
|
|
Axsome Therapeutics (AXSM) | 3.1 | $80M | +196% | 1.1M | 69.89 |
|
Bicycle Therapeutics Sponsored Ads (BCYC) | 2.7 | $70M | +23% | 3.5M | 20.09 |
|
Travere Therapeutics (TVTX) | 2.5 | $66M | 7.4M | 8.94 |
|
|
Intellia Therapeutics (NTLA) | 2.4 | $63M | +139% | 2.0M | 31.62 |
|
Editas Medicine (EDIT) | 2.1 | $55M | +105% | 7.1M | 7.80 |
|
Geron Corporation (GERN) | 2.1 | $55M | +6% | 26M | 2.12 |
|
Verona Pharma Sponsored Ads (VRNA) | 2.0 | $52M | 3.2M | 16.30 |
|
|
Apogee Therapeutics (APGE) | 2.0 | $51M | NEW | 2.4M | 21.30 |
|
Pacific Biosciences of California (PACB) | 1.9 | $50M | +313% | 6.0M | 8.35 |
|
Miragen Therapeutics (VRDN) | 1.8 | $46M | +131% | 3.0M | 15.34 |
|
Novocure Ord Shs (NVCR) | 1.6 | $40M | NEW | 2.5M | 16.15 |
|
Hillevax (HLVX) | 1.5 | $39M | NEW | 2.9M | 13.45 |
|
Repare Therapeutics Ord (RPTX) | 1.4 | $37M | +12% | 3.1M | 12.08 |
|
Agenus Com New (AGEN) | 1.4 | $36M | +5% | 32M | 1.13 |
|
4d Molecular Therapeutics In (FDMT) | 1.4 | $35M | 2.8M | 12.73 |
|
|
Autolus Therapeutics Spon Ads (AUTL) | 1.3 | $35M | 15M | 2.33 |
|
|
Neurocrine Biosciences (NBIX) | 1.3 | $34M | NEW | 300k | 112.50 |
|
Terns Pharmaceuticals (TERN) | 1.2 | $30M | +445% | 6.0M | 5.03 |
|
Rapt Therapeutics (RAPT) | 1.0 | $25M | +49% | 1.5M | 16.62 |
|
Beam Therapeutics (BEAM) | 0.9 | $24M | -22% | 1.0M | 24.05 |
|
Anaptysbio Inc Common (ANAB) | 0.9 | $24M | NEW | 1.3M | 17.96 |
|
Olema Pharmaceuticals (OLMA) | 0.9 | $24M | NEW | 1.9M | 12.35 |
|
Nurix Therapeutics (NRIX) | 0.9 | $24M | 3.0M | 7.86 |
|
|
Biosante Pharmaceuticals (ANIP) | 0.9 | $23M | -22% | 400k | 58.06 |
|
Amylyx Pharmaceuticals (AMLX) | 0.9 | $23M | NEW | 1.3M | 18.31 |
|
Biontech Se Sponsored Ads (BNTX) | 0.8 | $22M | NEW | 200k | 108.64 |
|
Dyne Therapeutics (DYN) | 0.8 | $22M | -3% | 2.4M | 8.96 |
|
Moderna (MRNA) | 0.8 | $21M | NEW | 200k | 103.29 |
|
Silence Therapeutics Ads (SLN) | 0.7 | $19M | 2.0M | 9.82 |
|
|
Point Biopharma Global | 0.7 | $19M | 2.8M | 6.67 |
|
|
Zura Bio Class A Ord Shs (ZURA) | 0.6 | $17M | 2.5M | 6.60 |
|
|
Orchard Therapeutics Spon Ads New | 0.6 | $16M | NEW | 2.0M | 7.73 |
|
Edgewise Therapeutics (EWTX) | 0.6 | $16M | 2.8M | 5.73 |
|
|
Prothena Corp SHS Put Option (PRTA) | 0.5 | $12M | 250k | 48.25 |
|
|
Nektar Therapeutics (NKTR) | 0.4 | $11M | +2% | 18M | 0.60 |
|
Morphic Hldg (MORF) | 0.4 | $11M | +117% | 471k | 22.91 |
|
Agios Pharmaceuticals (AGIO) | 0.4 | $11M | NEW | 422k | 24.75 |
|
Acumen Pharmaceuticals (ABOS) | 0.4 | $10M | -35% | 2.5M | 4.15 |
|
Nuvation Bio Com Cl A (NUVB) | 0.4 | $10M | 7.7M | 1.34 |
|
|
Vigil Neuroscience (VIGL) | 0.4 | $9.5M | 1.8M | 5.39 |
|
|
Relmada Therapeutics (RLMD) | 0.3 | $8.5M | 2.8M | 3.00 |
|
|
Astria Therapeutics (ATXS) | 0.3 | $7.7M | -38% | 1.0M | 7.46 |
|
10x Genomics Cl A Com (TXG) | 0.3 | $7.5M | NEW | 183k | 41.25 |
|
Novavax Com New (NVAX) | 0.3 | $7.2M | NEW | 1.0M | 7.24 |
|
Acelyrin (SLRN) | 0.2 | $5.6M | NEW | 551k | 10.17 |
|
Gh Research Ordinary Shares (GHRS) | 0.2 | $5.0M | 499k | 10.05 |
|
|
Syros Pharmaceuticals Com New (SYRS) | 0.1 | $3.3M | NEW | 829k | 3.95 |
|
Scholar Rock Hldg Corp (SRRK) | 0.1 | $2.5M | NEW | 354k | 7.10 |
|
Compass Pathways Sponsored Ads (CMPS) | 0.1 | $2.4M | -51% | 328k | 7.40 |
|
Heron Therapeutics (HRTX) | 0.1 | $2.1M | 2.1M | 1.03 |
|
|
89bio (ETNB) | 0.1 | $1.4M | -81% | 91k | 15.44 |
|
Century Therapeutics (IPSC) | 0.0 | $1.1M | -46% | 543k | 2.00 |
|
Past Filings by Deep Track Capital
SEC 13F filings are viewable for Deep Track Capital going back to 2021
- Deep Track Capital 2023 Q3 filed Nov. 14, 2023
- Deep Track Capital 2023 Q2 restated filed Sept. 6, 2023
- Deep Track Capital 2023 Q2 filed Aug. 14, 2023
- Deep Track Capital 2023 Q1 filed May 15, 2023
- Deep Track Capital 2022 Q4 filed Feb. 14, 2023
- Deep Track Capital 2022 Q3 filed Nov. 14, 2022
- Deep Track Capital 2022 Q2 filed Aug. 12, 2022
- Deep Track Capital 2022 Q1 filed May 16, 2022
- Deep Track Capital 2021 Q4 filed Feb. 14, 2022